NCT06128564

A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2023-11-29Est. Completion: 2026-03-04

Enrollment target: 13 participants

Locations

Chr de La Citadelle, Liège, Belgium
Hôpital Necker-Enfants Malades, Paris, France
Universitätsklinikum Essen, Essen, Germany
PU A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Lazio, Italy
Hospital Sant Joan De Deu, Esplugues de Llobregas, Barcelona, Spain
Great Ormond Street Hospital for Children, London, United Kingdom
John Radcliffe Hospital, Oxford, United Kingdom

Other microbiome trials you might be interested in

A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Single Intravenous Infusion of JWK007 in Patients With Duchenne Muscular Dystrophy (DMD)Phase 1Recruiting

Duchenne Muscular Dystrophy

This study is a single-center, single-arm, non-randomized, open-label, non-controlled, dose-escalation, prospective clin…

Chengdu, ChinaEst. completion Nov 13, 2029

View Trial →

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 SkippingPhase 3Recruiting

Muscular DystrophiesMuscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)Muscular Disorders, AtrophicMuscular DiseaseMusculoskeletal DiseasesNeuromuscular Diseases (NMD)

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.